CELU

$1.26

Post-MarketAs of Mar 17, 8:00 PM UTC

Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$1.26
Potential Upside
5%
Whystock Fair Value$1.32
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$36.34M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.79
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.10

Recent News

Proactive
Mar 12, 2026

Poolbeg Pharma adds CAR-T therapy expert to scientific advisory board

Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the AIM-listed clinical-stage biopharmaceutical company, has appointed Dr Adrian Kilcoyne to its Scientific Advisory Board, bringing more than 20 years of oncology and immunology drug development experience to the company. Kilcoyne is...

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Simply Wall St.
Aug 31, 2025

Celularity Second Quarter 2025 Earnings: US$1.02 loss per share (vs US$0.30 loss in 2Q 2024)

Celularity ( NASDAQ:CELU ) Second Quarter 2025 Results Key Financial Results Revenue: US$5.74m (down 53% from 2Q 2024...

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Simply Wall St.
Aug 14, 2025

Retail investors among Celularity Inc.'s (NASDAQ:CELU) largest shareholders, saw gain in holdings value after stock jumped 11% last week

NasdaqCM:CELU 1 Year Share Price vs Fair Value Explore Celularity's Fair Values from the Community and select yours Key...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.